Veröffentlichungen

Originalarbeiten, Bücher, Buchkapitel und Übersichtsartikel von Prof. Marcus Maurer

Verwendung: Beginnen Sie mit einer Übersicht über alle Publikationen. Verwenden Sie Tag-Links, um markierte Dokumente aufzulisten oder eine ganze Kategorie aufzulisten, z.B. Original Work (Originalarbeiten), Books (Bücher), Book Chapters (Buchkapitel), Reviews (Übersichtsartikel). Wenn Sie wissen, was Sie suchen, dann geben Sie diesen Begriff in das Suchfeld ein.

Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results

Filename 400. Maurer et al., AH resist. CSU AWARE 2 year, CEA 2020.pdf
Filesize 536,14 kB
Version o.401
Date added November 13, 2020
Downloaded 0 times
Category Original Work
Tags angioedema, Dermatology, Quality of life, urticaria
Authors Maurer, M., Giménez-Arnau, A., Ensina, L. F., Chu, C.-Y., Jaumont, X, and Tassinari, P.
Citation Maurer, M., Giménez-Arnau, A., Ensina, L. F., Chu, C.-Y., Jaumont, X, and Tassinari, P.: Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results. World Allergy Organ. J. 2020: 13; 100460.
Corresponding authors Maurer, M.
DocNum o.401
DocType PDF
IF 4.08
Publisher World Allergy Organ. J.
ReleaseDate 2020

Background: A Worldwide Antihistamine-Refractory Chronic Urticaria (CU) patient Evaluation (AWARE) is a non-interventional, multicenter study including patients from Europe, Central and Latin America, Asia-Pacific, and the Middle East. AWARE describes real-world evidence for CU, including clinical characteristics, treatment patterns and the impact on quality of life.

Methods: Over the 2-year study, therapy changes, angioedema occurrence, and patientreported outcomes (PROs) were recorded over 9 visits, including dermatology life quality index (DLQI) and 7-day urticaria activity score (UAS7). Data were stratified into subgroups: chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), or CSU þ CIndU.

Results: Out of 4838 patients analyzed, 9.9% were receiving no treatment for their CU symptoms at baseline, and 20.4% were receiving first-line non-sedating H1-antihistamine at approved doses. The predominant baseline therapy was up-dosed non-sedating H1-antihistamines (25.5%). By Visit 2, omalizumab was the overall most commonly used therapy (29.6%), increasing to 30.1% by the end of the study. Baseline DLQI scores for patients with CSU, CIndU and CSU þ CIndU were 8.3, 7.6 and 9.1, respectively; scores decreased over the study for CSU and CSU þ CIndU patients, but fluctuated for CIndU patients. Baseline angioedema occurrence was higher in CSU and CSU þ CIndU patients, reported in 45.4% and 45.5% of patients, respectively, compared to 17.0% in CIndU patients. By the final visit, angioedema had decreased to 11.9% and 11.2% for CSU and CSU þ CIndU, respectively, and 9.6% for CIndU.

Conclusion: CU patients are undertreated at baseline; after entering the AWARE study, more patients received appropriate treatment. However, over two thirds are not escalated to third-line treatments.

 

(Last update: 12.2023)

Number of original publications in peer-reviewed journals:580
Number of reviews in peer-reviewed journals:210
Number of publications (original work and reviews) in peer-reviewed journals:790
Cumulative IF for original publications in peer-reviewed journals:4196.39
Cumulative IF for reviews in peer-reviewed journals:1409.32
Cumulative IF of publications (original work & reviews) in peer-reviewed journals:5605.71
Total number of citations: 36,836, h-index: 99 (Web of Science December 2023)36836

Download-Information

Um die angebotenen Veröffentlichungen herunterladen zu können, müssen Sie sich einloggen. Wenn Sie das Login nicht kennen, schreiben Sie mir bitte Ihre Anfrage.